Back to News
Feb 12, 2026 4:00 PM

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market

Novo Nordisk A/S (NYSE:NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE:LLY) as competition intensifies in the fast-growing weight-loss market.

Currently, Novo markets Wegovy in prefilled injector pens.

Lilly began offering vials of Zepbound in 2024 amid widespread shortages, when demand outpaced its ability to manufacture sufficient pen devices.

Eli Lilly CEO Dave Ricks said earlier this month that vials have since become Lilly's most popular format, accounting for roughly one-third of new patients starting any weight-loss therapy.

The Bloomberg report adds that Novo Nordisk has not disclosed pricing details for its vial format. The company plans to introduce vials in the U.S. first before selling them in other markets.

Novo Nordisk CEO Mike Doustdar ...